Morbid obesity is an increasing medical problem in the western countries. It's related to comorbidities as diabetes mellitus, hypertension, OSAS, arthrosis and hypercholesterolemia. The Roux-en-Y Gastric Bypass (RYGB) is an effective surgical therapy for morbidly obese patients. A part of these patients will have disappointing results, and have weight regain on the long term. Some studies show more weight reduction by increasing the biliopancreatic limb in patients with morbid obesity. The objective of this study is to investigate the effect of a restrictive/extended pouch on weight reduction in morbidly obese patients undergoing RYGB-surgery. We hypothesize that the restrictive/extended pouch results in more weight reduction. The study design is a prospective, randomized control trial. The patients will be randomized in 2 groups: a standard RYGB (normal pouch) and restrictive/extended pouch RYGB.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
130
Rijnstate Hospital
Arnhem, Gelderland, Netherlands
Weight reduction
Excess weight loss (%EWL)
Time frame: 2 years
Change in comorbidities
Preoperatively the number of patients with comorbidities will be calculated. At two year follow-up this will be calculated again. Patients will be divided in groups: 1. comorbidity resolved 2. comorbidity improved 3. comorbidity unchanged 4. comorbidity worsened This will be done for diabetes mellitus, hypertension, dyslipidemia and OSAS.
Time frame: 2 years
Change in comorbidities
Preoperatively the number of patients with comorbidities will be calculated. At two year follow-up this will be calculated again. Patients will be divided in groups: 1. comorbidity resolved 2. comorbidity improved 3. comorbidity unchanged 4. comorbidity worsened This will be done for diabetes mellitus, hypertension, dislipidemia and OSAS.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.